Jiangsu Hengrui Pharmaceuticals (01276): HRS-5765 tablets obtain drug clinical trial approval notification.
Hengrui Medicine (01276) announced that its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., has recently received the Drug Clinical Trial Approval Notification issued by the National Medical Products Administration for HRS-5765 tablets, and will soon begin clinical trials.
Jiangsu Hengrui Pharmaceuticals (01276) announces that its subsidiary, Chengdu Shengdi Pharmaceuticals Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for a clinical trial of HRS-5765 tablets. The trial will be conducted soon.
HRS-5765 tablets are a type 1 new drug developed independently by the company. Preclinical data shows that HRS-5765 can significantly improve heart function and disease. There are currently no similar drugs approved for sale domestically or internationally. As of now, the total research and development investment in the HRS-5765 tablet project is approximately 13.8 million yuan (unaudited).
Related Articles
Keep bought back 200,000 shares on April 10 for 594,300 Hong Kong dollars.
TIAN LUN GAS (01600) spent 766,000 Hong Kong dollars to repurchase 265,000 shares on April 10th.
WEIGAO GROUP (01066) spent 515,800 Hong Kong dollars to repurchase 140,000 shares on April 10th.
Keep bought back 200,000 shares on April 10 for 594,300 Hong Kong dollars.
TIAN LUN GAS (01600) spent 766,000 Hong Kong dollars to repurchase 265,000 shares on April 10th.
WEIGAO GROUP (01066) spent 515,800 Hong Kong dollars to repurchase 140,000 shares on April 10th.
RECOMMEND
